Goldman Sachs Group Inc Myriad Genetics Inc Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Myriad Genetics Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 714,095 shares of MYGN stock, worth $3.51 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
714,095
Previous 714,095
-0.0%
Holding current value
$3.51 Million
Previous $6.33 Million
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding MYGN
# of Institutions
240Shares Held
95.3MCall Options Held
95.4KPut Options Held
18.2K-
Black Rock Inc. New York, NY15.2MShares$74.5 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.7MShares$52.5 Million0.0% of portfolio
-
State Street Corp Boston, MA5.27MShares$25.9 Million0.0% of portfolio
-
Disciplined Growth Investors Inc Minneapolis, MN4.73MShares$23.3 Million0.98% of portfolio
-
Wellington Management Group LLP Boston, MA4.59MShares$22.6 Million0.01% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $397M
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...